Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Operating Leases (2019 - 2025)

China Pharma Holdings' Operating Leases history spans 7 years, with the latest figure at $111548.0 for Q4 2025.

  • For Q4 2025, Operating Leases rose 183.67% year-over-year to $111548.0; the TTM value through Dec 2025 reached $111548.0, up 183.67%, while the annual FY2025 figure was $111548.0, 183.67% up from the prior year.
  • Operating Leases reached $111548.0 in Q4 2025 per CPHI's latest filing, down from $198583.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $198583.0 in Q3 2025 to a low of $20008.0 in Q1 2024.
  • Average Operating Leases over 5 years is $79482.4, with a median of $73863.0 recorded in 2021.
  • Peak YoY movement for Operating Leases: soared 307.55% in 2022, then plummeted 81.08% in 2023.
  • A 5-year view of Operating Leases shows it stood at $85282.0 in 2021, then crashed by 52.57% to $40445.0 in 2022, then dropped by 1.32% to $39910.0 in 2023, then dropped by 1.47% to $39323.0 in 2024, then soared by 183.67% to $111548.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Operating Leases are $111548.0 (Q4 2025), $198583.0 (Q3 2025), and $39323.0 (Q4 2024).